Privium Fund Management B.V. Recursion Pharmaceuticals, Inc. Transaction History
Privium Fund Management B.V.
- $436 Million
- Q4 2024
A detailed history of Privium Fund Management B.V. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 119,000 shares of RXRX stock, worth $729,470. This represents 0.18% of its overall portfolio holdings.
Number of Shares
119,000
Previous 78,000
52.56%
Holding current value
$729,470
Previous $514,000
56.42%
% of portfolio
0.18%
Previous 0.13%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
341Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$208 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$198 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$152 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$106 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$89.9 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.11B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...